Table 2.
Comorbidities and disease management of the study population.
| Moderate and severe asthma | P | Severe asthma | P | |||
|---|---|---|---|---|---|---|
| without BQ (146) | with BQ (78) | without BQ (66) | with BQ (71) | |||
| Comorbidity | ||||||
| NSAIDs allergy | 25 (17.1%) | 13 (16.7%) | 0.93 | 19 (28.8%) | 11 (15.5%) | 0.060 |
| Rhinitis | 50 (34.2%) | 22 (28.2%) | 0.36 | 21 (31.8%) | 21 (29.6%) | 0.78 |
| Sinusitis | 3 (2.1%) | 8 (10.3%) | 0.018 | 1 (1.5%) | 8 (11.3%) | 0.034 |
| Nasal polyps | 19 (13.0%) | 22 (28.2%) | 0.005 | 11 (16.7%) | 20 (28.2%) | 0.11 |
| Obesity | 46 (31.5%) | 18 (23.1%) | 0.18 | 23 (34.8%) | 16 (22.5%) | 0.11 |
| WRA | 25 (17.1%) | 14 (17.9%) | 0.88 | 10 (15.2%) | 12 (16.9%) | 0.78 |
| Disease management | ||||||
| Cortisone-dependent | 5 (3.4%) | 27 (34.6%) | < 0.001 | 4 (6.1%) | 27 (38.0%) | < 0.001 |
| Budesonide (μg/d) | 1040 (640,1600) | 1280 (640,1600) | 0.37 | 1440 (800,1600) | 1400 (640,1600) | 0.29 |
| ICS dose category | 0.14 | 0.61 | ||||
| Low | 30 (20.5%) | 10 (12.8%) | 5 (7.6%) | 9 (12.7%) | ||
| Med | 42 (28.8%) | 18 (23.1%) | 13 (19.7%) | 14 (19.7%) | ||
| High | 74 (50.7%) | 50 (64.1%) | 48 (72.7%) | 48 (67.6%) | ||
| LAMA | 39 (26.7%) | 54 (69.2%) | < 0.001 | 29 (43.9%) | 53 (74.6%) | < 0.001 |
| Azithromycin | 10 (6.8%) | 26 (33.3%) | < 0.001 | 8 (12.1%) | 26 (36.6%) | < 0.001 |
| Omalizumab | 18 (12.3%) | 15 (19.2%) | 0.16 | 18 (27.3%) | 15 (21.1%) | 0.40 |
| Mepolizumab | 4 (2.7%) | 5 (6.4%) | 0.28 | 4 (6.1%) | 5 (7.0%) | 1.00 |
| Anti-leukotriene | 57 (39.0%) | 51 (65.4%) | < 0.001 | 39 (59.1%) | 48 (67.6%) | 0.30 |
| Theophylline | 2 (1.4%) | 1 (1.3%) | 1.00 | 2 (3.0%) | 1 (1.4%) | 0.61 |
Continuous variables expressed as mean (SD) or median (p25, p75); categorical data expressed as percentage n (%); BQ: non-cystic fibrosis bronchiectasis; NSAIDs, allergy to nonsteroidal anti-inflammatory drugs; LAMA: long-acting muscarinic receptor antagonists; ICS: Inhaled Corticosteroid. Significant p values in bold font.